The prevalence of metabolic syndrome in patients with hidradenitis suppurativa - 14/03/14
Abstract |
Background |
Metabolic syndrome is a multifaceted disorder strongly associated with increased risk for development of cardiovascular disease. Chronic inflammatory diseases have been associated with metabolic syndrome. Hidradenitis suppurativa is a chronic inflammatory skin disease with significant physical and emotional sequelae.
Objective |
We sought to investigate a possible association between hidradenitis suppurativa and metabolic syndrome.
Methods |
A retrospective chart review of all dermatology clinic encounters over an 18-month period identified 366 patients with an appropriate diagnosis of hidradenitis suppurativa. A control population was created from patients seen in the same clinic during the same time period for the diagnoses of either keloids or verruca vulgaris using the matching criteria of age ±5 years, race, and gender. All participants were examined for characteristics of the metabolic syndrome as defined by the National Cholesterol Education Program Adult Treatment Program III guidelines.
Results |
The prevalence of metabolic syndrome in patients with hidradenitis suppurativa was 50.6%, which was significantly higher than the control group at 30.2% (P < .001).
Limitations |
This was a retrospective review. Some participants could not be analyzed for metabolic syndrome presence as a result of missing data points.
Conclusion |
Our results indicate that patients with hidradenitis suppurativa may be at high risk for metabolic syndrome.
Le texte complet de cet article est disponible en PDF.Key words : acne inversa, dyslipidemia, glucose intolerance, hidradenitis suppurativa, hypertension, metabolic syndrome, obesity, Velpeau disease, Verneuil disease
Abbreviations used : CI, HDL, IL
Plan
| The Henry Ford Medical Center Department of Dermatology receives support from and this study was funded by the Livingood Fund and Rodzik Fund, neither of which had any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. |
|
| Disclosure: Dr Hamzavi has served and/or currently serves as an investigator in clinical trial activities for the following companies: Galderma, ViroXis, Abbvie, La Roche–Posay, Dow, Centocor, Amgen, Clinuvel, and Pfizer. Dr Hamzavi also serves as a consultant for COMBE. Mr Gold, Dr Reeder, and Ms Mahan have no conflicts of interest to declare. |
Vol 70 - N° 4
P. 699-703 - avril 2014 Retour au numéro
Article précédent
- Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: A nationwide population-based cohort study
- Meng-Sui Lee, Ruey-Yi Lin, Mei-Shu Lai
- Cutaneous delayed-type hypersensitivity in patients with atopic dermatitis: Reactivity to surfactants
- Cristin N. Shaughnessy, Dana Malajian, Donald V. Belsito
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?